enoch-logo-2_edited.png

Our vision is to make gene therapy
for neurodegenerative diseases
safer, more effective,
and more affordable

 

THE PROBLEM

Gene therapy uses genes to prevent or cure diseases. Essentially, if a disorder is caused by abnormal cellular functioning, we introduce new genetic material that will fix the problem. Gene therapy is already used to treat diseases like retinal dystrophy and some forms of cancer. However, with the good news also comes some bad news.

You might have read about unexpected inefficacy and negative side effects of gene therapies. That is because, in order for gene therapy to be effective and safe, we need to know:

  • What are the right genes to target?

  • What is the overall effect of adding new genes?

Unfortunately these are not easy questions. Gene therapy modifies only a few genes at a time; however, there are thousands of genes that affect each other through complex regulatory networks. If you want to test the effects of modifying each gene, one at a time, you might need two weeks, you would need 1000 years for two genes at a time, and you would need over a million years for three genes at a time.

So the main problem of gene therapy discovery is that there is not enough time to experimentally test every possible target. The current workaround is to rely on conflicting and often biased scientific literature to narrow down the list. This is an inefficient process that delays the introduction of new therapies.


We think we can do better.

 

OUR SOLUTION

Enoch's AI identifies high-quality therapeutic formulations for neurodegenerative disease. Our cutting-edge ML derives dynamic representations of the regulatory networks governing cell behavior, learning interpretable models from single-cell sequencing and perturbation experiments. Enoch uses natural aging as a disease model, permitting rapid and powerful hit validation by translating across species. Our causal, transparent ML and adaptable model system enable us to provide high-confidence predictions for multiple disorders.

 

TEAM ENOCH

Daniel-6 (1).jpg

DAN ACKER, PHD

Co-founder & Data Scientist

kimbrell-katie.jpg

KATIE KIMBRELL

Co-founder & Neuroscientist

 

NEWS

IMG_0811_edited.jpg

TEAM ENOCH WINS NSF I-CORPS PITCH COMPETITION

July 18, 2019

Enoch was the winning team among the Summer 2019 Brandeis NSF I-Corps Cohort. The program involved business model development and market validation through customer interviews. We talked to over a dozen bench scientists, data scientists, software engineers, founders, and executives. The program finale was a pitch competition at Brandeis' HackMyPhD event.

 

GET IN TOUCH

 

©2019 by Enoch Therapeutics.